Journal
MOLECULAR CANCER THERAPEUTICS
Volume 7, Issue 3, Pages 439-448Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-07-2328
Keywords
-
Categories
Funding
- FOGARTY INTERNATIONAL CENTER [R03TW006273] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS058156, R01NS054193, R01NS042893, U54NS045309, R21NS054143, R21NS047298, U01NS052465, R01NS044556] Funding Source: NIH RePORTER
- FIC NIH HHS [R03 TW006273-01A1, 1 R03 TW 006273-01, R03 TW006273] Funding Source: Medline
- NINDS NIH HHS [R01 NS042893-01A1, 1 F32 NS 058156-01, U54 NS045309-010005, R21 NS047298, 1 U01 NS 052465-01, R01 NS054193, 1 R21 NS 047298-01, 1 R01 NS 44556-01, R01 NS054193-01A1, F32 NS058156-01A1, NS 445561, 1 R01 NS 054193-01, R21 NS054143, 1 R21 NS 054143-01, R01 NS042893, U54 NS 045309-01, U54 NS045309, R01 NS044556-01, R21 NS054143-01A2, R01 NS 42893-01, R21 NS047298-01, U01 NS052465, R01 NS044556, R01 NS044556-05, F32 NS058156] Funding Source: Medline
Ask authors/readers for more resources
Cancer poses a tremendous therapeutic challenge worldwide, highlighting the critical need for developing novel therapeutics. A promising cancer treatment modality is gene therapy, which is a form of molecular medicine designed to introduce into target cells genetic material with therapeutic intent. Anticancer gene therapy strategies currently used in preclinical models, and in some cases in the clinic, include proapoptotic genes, oncolytic/replicative vectors, conditional cytotoxic approaches, inhibition of angiogenesis, inhibition of growth factor signaling, inactivation of oncogenes, inhibition of tumor invasion and stimulation of the immune system. The translation of these novel therapeutic modalities from the preclinical setting to the clinic has been driven by encouraging preclinical efficacy data and advances in gene delivery technologies. One area of intense research involves the ability to accurately regulate the levels of therapeutic gene expression to achieve enhanced efficacy and provide the capability to switch gene expression off completely if adverse side effects should arise. This feature could also be implemented to switch gene expression off when a successful therapeutic outcome ensues. Here, we will review recent developments related to the engineering of transcriptional switches within gene delivery systems, which could be implemented in clinical gene therapy applications directed at the treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available